array(3) { ["company_details"]=> array(13) { ["name"]=> string(29) "Regeneron Pharmaceuticals Inc" ["slug"]=> string(38) "c469a-us-regeneron-pharmaceuticals-inc" ["logo"]=> string(84) "https://images.businessradar.com/linkedin_logos/b5187988-884a-43b7-980d-e1555548ab77" ["description"]=> string(868) "At Regeneron we believe that when the right idea finds the right team, powerful change is possible. As we work across our expanding global network to invent, develop and commercialize life-transforming medicines for people with serious diseases, we’re establishing new ways to think about science, manufacturing and commercialization. And new ways to think about health. Connect with us so we can learn more about you, and you can learn more about our biopharmaceutical medicines. And join us, as we build a future we believe in. Please visit www.regeneron.com/social-media-terms for information on how to engage with us on social media. An important note about privacy: Regeneron is committed to your privacy and will not ask for sensitive personal information such as social security number, date of birth or bank account details via email or social media. " ["address_street"]=> string(25) "777 Old Saw Mill River Rd" ["address_place"]=> string(9) "Tarrytown" ["address_region"]=> string(8) "New York" ["founding_date"]=> string(10) "1988-02-08" ["website_domain"]=> string(13) "regeneron.com" ["website_url"]=> string(25) "https://www.regeneron.com" ["industry_codes"]=> array(1) { [0]=> string(27) "Pharmaceutical Preparations" } ["employee_count"]=> int(10368) ["article_count"]=> int(2748) } ["articles"]=> array(9) { [0]=> array(7) { ["title_en"]=> string(97) "Harvest Portfolios Group Inc. Sells 7,046 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Harvest Portfolios Group Inc. lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 13.7% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,340 shares of the biopharmaceutical company's sto" ["url"]=> string(144) "https://www.marketbeat.com/instant-alerts/harvest-portfolios-group-inc-sells-7046-shares-of-regeneron-pharmaceuticals-inc-nasdaqregn-2024-11-06/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/dccc8212-3a85-4003-bde6-62fcf8c852ab" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-11-06" ["categories"]=> array(7) { [0]=> string(11) "Acquisition" [1]=> string(24) "Stock Research & Ratings" [2]=> string(11) "Regulations" [3]=> string(12) "Stock Market" [4]=> string(10) "Divestment" [5]=> string(18) "General Investment" [6]=> string(31) "Financial Update/Profit Warning" } } [1]=> array(7) { ["title_en"]=> string(90) "Regeneron Pharmaceuticals Stock: Price Decline After Q3 Report Exaggerated (Piper Sandler)" ["snippet_en"]=> string(107) "Regeneron Pharmaceuticals Stock: Price Decline After Q3 Report Exaggerated (Piper Sandler) | aktiencheck.de" ["url"]=> string(122) "https://www.aktiencheck.de/exklusiv/Artikel-Regeneron_Pharmaceuticals_Aktie_Kursrueckgang_Q3_Bericht_uebertrieben-17763808" ["image_url"]=> string(78) "https://images.businessradar.com/articles/3c2c544c-f9cb-4429-af17-5e404cd29198" ["source"]=> string(14) "aktiencheck.de" ["publication_date"]=> string(10) "2024-11-05" ["categories"]=> array(3) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(24) "Quarterly/Annual Figures" [2]=> string(12) "Stock Market" } } [2]=> array(7) { ["title_en"]=> string(58) "Regeneron Pharmaceuticals: Price target reduction (Truist)" ["snippet_en"]=> string(69) "Regeneron Pharmaceuticals: Price target cut (Truist) | aktiencheck.de" ["url"]=> string(94) "https://www.aktiencheck.de/exklusiv/Artikel-Regeneron_Pharmaceuticals_Kurszielsenkung-17759728" ["image_url"]=> NULL ["source"]=> string(14) "aktiencheck.de" ["publication_date"]=> string(10) "2024-11-05" ["categories"]=> array(2) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(12) "Stock Market" } } [3]=> array(7) { ["title_en"]=> string(92) "Regeneron, ‘high-dose’ Eylia “continues sluggish performance”… stock price ↓ 10%" ["snippet_en"]=> string(39) "Reporter Shin Chang-min of Biospectator" ["url"]=> string(59) "http://m.biospectator.com/view/news_view.php?varAtcId=23480" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1cafaca8-ae04-4e95-85d9-782f21dada1c" ["source"]=> string(16) "biospectator.com" ["publication_date"]=> string(10) "2024-11-05" ["categories"]=> array(1) { [0]=> string(12) "Stock Market" } } [4]=> array(7) { ["title_en"]=> string(112) "Empire Life Investments Inc. Makes New $5.03 Million Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)" ["snippet_en"]=> string(300) "Empire Life Investments Inc. purchased a new stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the third quarter, according to its most recent filing with the SEC. The firm purchased 4,785 shares of the biopharmaceutical company's stock, valued at approximately $5,03" ["url"]=> string(76) "https://www.marketbeat.com/instant-alerts/nasdaq-regn-sec-filing-2024-11-03/" ["image_url"]=> string(78) "https://images.businessradar.com/articles/1250fdd7-ae26-483d-bfbb-211135737c7f" ["source"]=> string(14) "marketbeat.com" ["publication_date"]=> string(10) "2024-11-03" ["categories"]=> array(5) { [0]=> string(19) "Investment Requests" [1]=> string(11) "Regulations" [2]=> string(12) "Stock Market" [3]=> string(18) "General Investment" [4]=> string(31) "Financial Update/Profit Warning" } } [5]=> array(7) { ["title_en"]=> string(99) "BMO Cuts Regeneron Price Target Following Eylea HD Struggles, Competitive Concerns By Investing.com" ["snippet_en"]=> string(85) "BMO Cuts Regeneron Price Target Following Eylea HD Struggles and Competition Concerns" ["url"]=> string(172) "https://fr.investing.com/news/company-news/bmo-reduit-lobjectif-de-cours-de-regeneron-suite-aux-difficultes-deylea-hd-et-aux-inquietudes-liees-a-la-concurrence-93CH-2626510" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-11-03" ["categories"]=> array(3) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(11) "Competition" [2]=> string(12) "Stock Market" } } [6]=> array(7) { ["title_en"]=> string(70) "Regeneron shares drop as higher-dose Eylea drug misses sales estimates" ["snippet_en"]=> string(230) "By Christy Santhosh (Reuters) – U.S. drugmaker Regeneron Pharmaceuticals on Thursday reported weaker-than-expected quarterly sales of the higher dose version of its blockbuster eye disease drug Eylea, sending its shares down 9%." ["url"]=> string(94) "https://srnnews.com/regeneron-beats-results-estimates-on-demand-for-eczema-treatment-eye-drug/" ["image_url"]=> NULL ["source"]=> string(11) "srnnews.com" ["publication_date"]=> string(10) "2024-11-02" ["categories"]=> array(2) { [0]=> string(24) "Quarterly/Annual Figures" [1]=> string(12) "Stock Market" } } [7]=> array(7) { ["title_en"]=> string(104) "Regeneron price target lowered following Eylea HD difficulties and competitive concerns By Investing.com" ["snippet_en"]=> string(98) "Regeneron's price target revised downward following Eylea HD difficulties and competitive concerns" ["url"]=> string(172) "https://fr.investing.com/news/company-news/lobjectif-de-cours-de-regeneron-revu-a-la-baisse-suite-aux-difficultes-deylea-hd-et-aux-inquietudes-concurrentielles-93CH-2626490" ["image_url"]=> NULL ["source"]=> string(13) "investing.com" ["publication_date"]=> string(10) "2024-11-02" ["categories"]=> array(2) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(12) "Stock Market" } } [8]=> array(7) { ["title_en"]=> string(54) "(3⁺) REGENERON - Can you buy the dip by the numbers?" ["snippet_en"]=> string(143) "Regeneron stock was one of the big losers in the Nasdaq 100 yesterday. It took third place on the losers list. Are there new opportunities now?" ["url"]=> string(87) "https://stock3.com/news/regeneron-kann-man-den-einbruch-nach-den-zahlen-kaufen-15646145" ["image_url"]=> NULL ["source"]=> string(10) "stock3.com" ["publication_date"]=> string(10) "2024-11-02" ["categories"]=> array(2) { [0]=> string(24) "Stock Research & Ratings" [1]=> string(12) "Stock Market" } } } ["category_annotations"]=> array(30) { [0]=> array(2) { ["name"]=> string(12) "Stock Market" ["count"]=> int(263) } [1]=> array(2) { ["name"]=> string(8) "Epidemic" ["count"]=> int(201) } [2]=> array(2) { ["name"]=> string(5) "Legal" ["count"]=> int(196) } [3]=> array(2) { ["name"]=> string(24) "Quarterly/Annual Figures" ["count"]=> int(129) } [4]=> array(2) { ["name"]=> string(17) "Academic Research" ["count"]=> int(116) } [5]=> array(2) { ["name"]=> string(5) "Award" ["count"]=> int(116) } [6]=> array(2) { ["name"]=> string(5) "Event" ["count"]=> int(93) } [7]=> array(2) { ["name"]=> string(24) "Stock Research & Ratings" ["count"]=> int(79) } [8]=> array(2) { ["name"]=> string(13) "Collaboration" ["count"]=> int(67) } [9]=> array(2) { ["name"]=> string(10) "Litigation" ["count"]=> int(66) } [10]=> array(2) { ["name"]=> string(18) "General Investment" ["count"]=> int(61) } [11]=> array(2) { ["name"]=> string(31) "Financial Update/Profit Warning" ["count"]=> int(59) } [12]=> array(2) { ["name"]=> string(18) "Expansion & Growth" ["count"]=> int(57) } [13]=> array(2) { ["name"]=> string(15) "Market Movement" ["count"]=> int(56) } [14]=> array(2) { ["name"]=> string(11) "Acquisition" ["count"]=> int(53) } [15]=> array(2) { ["name"]=> string(11) "Competition" ["count"]=> int(43) } [16]=> array(2) { ["name"]=> string(14) "Product Launch" ["count"]=> int(40) } [17]=> array(2) { ["name"]=> string(5) "R & D" ["count"]=> int(38) } [18]=> array(2) { ["name"]=> string(14) "Issuing Shares" ["count"]=> int(37) } [19]=> array(2) { ["name"]=> string(8) "Verdicts" ["count"]=> int(37) } [20]=> array(2) { ["name"]=> string(15) "Deals & Tenders" ["count"]=> int(37) } [21]=> array(2) { ["name"]=> string(21) "Competitive Behaviour" ["count"]=> int(35) } [22]=> array(2) { ["name"]=> string(46) "Management of Legal and Regulatory Environment" ["count"]=> int(33) } [23]=> array(2) { ["name"]=> string(12) "Board Change" ["count"]=> int(32) } [24]=> array(2) { ["name"]=> string(13) "Data Security" ["count"]=> int(31) } [25]=> array(2) { ["name"]=> string(27) "Business Model & Innovation" ["count"]=> int(28) } [26]=> array(2) { ["name"]=> string(14) "Product Review" ["count"]=> int(28) } [27]=> array(2) { ["name"]=> string(24) "Access and affordability" ["count"]=> int(25) } [28]=> array(2) { ["name"]=> string(11) "Sponsorship" ["count"]=> int(21) } [29]=> array(2) { ["name"]=> string(21) "Intellectual Property" ["count"]=> int(20) } } } c469a-us-regeneron-pharmaceuticals-inc